A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1573-7217

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns ; volume:182 ; number:3 ; day:10 ; month:6 ; year:2020 ; pages:643-654 ; date:8.2020
Breast cancer research and treatment ; 182, Heft 3 (10.6.2020), 643-654, 8.2020

Creator: Tzikas, Anna-Karin
Nemes, Szilard
Linderholm, Barbro K.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10549-020-05727-x

URN: urn:nbn:de:101:1-2020082319211766600176

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Tzikas, Anna-Karin
Nemes, Szilard
Linderholm, Barbro K.
SpringerLink (Online service)

Other Objects (12)

Metastatic Triple-Negative Breast Cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Metastatic Triple-Negative Breast Cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Related objects

Reset password